Drug Delivery


Daiichi Sankyo inks Glycotope ADC deal

By Flora Southey

Daiichi Sankyo Company has signed an option agreement to develop Glycotope’s antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.

Novartis HQ in Basel, Switzerland (source Novartis)

Novartis to pay $3.9 bn for radiopharma drug & biz

By Flora Southey

Novartis has announced plans to buy radiopharmaceutical firm Advanced Accelerator Applications (AAA), which will add neuroendocrine tumour treatment Lutathera to its portfolio.


Titan tests implant tech to curb opioid overdose

By Flora Southey

Titan has teamed with Opiant to investigate skin implant technology in the administration of opioid antagonists over extended periods, to combat opioid relapse and overdose in outpatients.